Literature DB >> 1475221

Monoclonal antibodies in hapten immunoassays.

O N Chappey1, P Sandouk, J M Scherrmann.   

Abstract

This review deals with the potency of monoclonal antibodies (MAbs) to haptens in immunoassays. Specificity and affinity of MAbs to haptens are the major determinants to be considered. Specificity of MAbs depends on the selection of the hapten coupling site to the carrier protein and the antigen used for the screening of MAbs. Nevertheless, cross-reactivity can occur with compounds related to the hapten. This polyspecificity may be circumvented with the use of many MAbs, as has been demonstrated for MAbs to cyclosporine. Affinity of MAbs to haptens is often lower than that of corresponding polyclonal antibodies (PAbs), thereby limiting assay sensitivity. Low affinity is more frequently observed with low molecular weight (100-300) haptens than with larger haptens, such as digoxin or cyclosporine. Affinity enhancement by increasing resemblance to the immunogen can be effective in resolving the lack of sensitivity. With suitable selection strategies. MAbs exhibit real advantages over classical PAbs to haptens because large amounts of worldwide standardized reagents can be prepared.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1475221     DOI: 10.1023/a:1015890208714

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  32 in total

1.  Ranitidine cross-reactivity in the EMIT d.a.u. Monoclonal Amphetamine/Methamphetamine Assay.

Authors:  K L Kelly
Journal:  Clin Chem       Date:  1990-07       Impact factor: 8.327

2.  Adenosine 3',5' cyclic monophosphate assay at 10-15 mole level.

Authors:  H L Cailla; M S Racine-Weisbuch; M A Delaage
Journal:  Anal Biochem       Date:  1973-12       Impact factor: 3.365

3.  Radioimmunoassay and saturation analysis. Basic principles and theory.

Authors:  R P Ekins
Journal:  Br Med Bull       Date:  1974-01       Impact factor: 4.291

4.  Potential of monoclonal antibodies to improve therapeutic monitoring of cyclosporine.

Authors:  V Quesniaux; R Tees; M H Schreier; G Maurer; M H van Regenmortel
Journal:  Clin Chem       Date:  1987-01       Impact factor: 8.327

5.  High-affinity monoclonal antibodies to the cardiac glycoside, digoxin.

Authors:  M M Hunter; M N Margolies; A Ju; E Haber
Journal:  J Immunol       Date:  1982-09       Impact factor: 5.422

Review 6.  On the specificity of antibodies.

Authors:  F F Richards; W H Konigsberg; R W Rosenstein; J M Varga
Journal:  Science       Date:  1975-01-17       Impact factor: 47.728

7.  Molecular recognition and the future of monoclonal antibodies.

Authors:  D Lane; H Koprowski
Journal:  Nature       Date:  1982-03-18       Impact factor: 49.962

8.  Phenotypic and genotypic characterization of monoclonal anti-digoxin antibodies.

Authors:  S H Pincus; W A Watson; S Harris; L P Ewing; C J Stocks; D E Rollins
Journal:  Life Sci       Date:  1984-07-23       Impact factor: 5.037

9.  Selection of monoclonal anti-digoxin antibodies with appropriate binding characteristics for immunodiagnostic purposes.

Authors:  S D Kyurkchiev; S N Tyutyullkova; I R Kehayov
Journal:  Methods Find Exp Clin Pharmacol       Date:  1990-05

10.  Purification and characterization of monoclonal antibodies to alpha-linolenic acid.

Authors:  F Buffière; J Cook-Moreau; N Gualde; M Rigaud
Journal:  J Lipid Mediat       Date:  1989 Mar-Apr
View more
  3 in total

Review 1.  Stereoselectivity of antibodies for the bioanalysis of chiral drugs.

Authors:  P A Got; J M Scherrmann
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

2.  Development of a competitive enzyme-linked immunosorbent assay for therapeutic drug monitoring of afatinib.

Authors:  Rintaro Sogawa; Tetsuya Saita; Yuta Yamamoto; Sakiko Kimura; Yutaka Narisawa; Shinya Kimura; Masashi Shin
Journal:  J Pharm Anal       Date:  2018-09-18

3.  Synthesis of Zearalenone Immunogen and Comparative Analysis of Antibody Characteristics.

Authors:  Yanan Wang; Xiaofei Wang; Haitang Zhang; Jinqing Jiang; Hanna Fotina
Journal:  Int J Anal Chem       Date:  2021-07-26       Impact factor: 1.885

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.